These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31199966)

  • 1. A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome.
    Kobashi K; Nitti V; Margolis E; Sand P; Siegel S; Khandwala S; Newman D; MacDiarmid SA; Kan F; Michaud E
    Urology; 2019 Sep; 131():77-82. PubMed ID: 31199966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.
    Peters KM; Carrico DJ; Perez-Marrero RA; Khan AU; Wooldridge LS; Davis GL; Macdiarmid SA
    J Urol; 2010 Apr; 183(4):1438-43. PubMed ID: 20171677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS).
    Martin-Garcia M; Crampton J
    Physiotherapy; 2019 Dec; 105(4):469-475. PubMed ID: 30862384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
    Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA
    J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
    Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
    Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tibial nerve stimulation using a wearable device for overactive bladder.
    Liao L; Li X; Chong T; Chen Q; Xu Z; Huang B; Chen M; Li H; Wei Z; Shao Y; Lu J; Pang R; Li X; Wang Y
    BJU Int; 2024 Jun; 133(6):760-769. PubMed ID: 38468422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.
    Goudelocke C; Xavier K; Pecha B; Burgess K; Perrouin-Verbe MA; Krlin R; Michaels J; Shah S; Peyronnet B; Zaslau S; Champs M; Papi B; Bittner K; Elterman D; Nitti V
    Neurourol Urodyn; 2023 Apr; 42(4):761-769. PubMed ID: 36917003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study to assess the effectiveness and safety of the BlueWind System in the treatment of patients diagnosed with urgency urinary incontinence.
    Heesakkers JPFA; Toozs-Hobson P; Sutherland SE; Digesu A; Amundsen CL; McCrery RJ; De Wachter S; Kean ER; Martens F; Benson K; Ferrante KL; Cline KJ; Padron OF; Giusto L; Lane FL; Dmochowski RR
    Neurourol Urodyn; 2024 Sep; 43(7):1491-1503. PubMed ID: 38634481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous tibial nerve stimulation versus sham efficacy in the treatment of refractory overactive bladder: outcomes following a shortened 6-week protocol, a prospective randomized controlled trial.
    Lashin AM; Eltabey NA; Wadie BS
    Int Urol Nephrol; 2021 Dec; 53(12):2459-2467. PubMed ID: 34601705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an implant technique and early experience using a novel implantable pulse generator with a quadripolar electrode array at the tibial nerve for refractory overactive bladder.
    Sirls LT; Schonhoff A; Waldvogel A; Peters KM
    Neurourol Urodyn; 2023 Feb; 42(2):427-435. PubMed ID: 36573835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
    Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
    J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcutaneous tibial nerve home stimulation for overactive bladder in women with Parkinson's disease: A randomized clinical trial.
    Araujo TG; Schmidt AP; Sanches PRS; Silva Junior DP; Rieder CRM; Ramos JGL
    Neurourol Urodyn; 2021 Jan; 40(1):538-548. PubMed ID: 33326648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Home-based transcutaneous tibial nerve stimulation for overactive bladder syndrome: a randomized, controlled study.
    Cava R; Orlin Y
    Int Urol Nephrol; 2022 Aug; 54(8):1825-1835. PubMed ID: 35622269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome.
    Rostaminia G; Chang C; Pincus JB; Sand PK; Goldberg RP
    Int Urogynecol J; 2019 Oct; 30(10):1735-1745. PubMed ID: 30498931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study.
    Peters KM; Carrico DJ; MacDiarmid SA; Wooldridge LS; Khan AU; McCoy CE; Franco N; Bennett JB
    Neurourol Urodyn; 2013 Jan; 32(1):24-9. PubMed ID: 22674493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children.
    Barroso U; Viterbo W; Bittencourt J; Farias T; Lordêlo P
    J Urol; 2013 Aug; 190(2):673-7. PubMed ID: 23422257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: Randomized control trial.
    Ramírez-García I; Blanco-Ratto L; Kauffmann S; Carralero-Martínez A; Sánchez E
    Neurourol Urodyn; 2019 Jan; 38(1):261-268. PubMed ID: 30311692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.